- Home
- ACAD vs SRRK Comparison
ACAD vs SRRK Comparison
Compare ACAD & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- SRRK
- Stock Information
- Founded
- ACAD 1993
- SRRK 2012
- Country
- ACAD United States
- SRRK United States
- Employees
- ACAD N/A
- SRRK N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- SRRK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACAD Health Care
- SRRK Health Care
- Exchange
- ACAD Nasdaq
- SRRK Nasdaq
- Market Cap
- ACAD 3.5B
- SRRK 3.0B
- IPO Year
- ACAD 2004
- SRRK 2018
- Fundamental
- Price
- ACAD $21.09
- SRRK $27.93
- Analyst Decision
- ACAD Buy
- SRRK Strong Buy
- Analyst Count
- ACAD 20
- SRRK 10
- Target Price
- ACAD $29.25
- SRRK $46.11
- AVG Volume (30 Days)
- ACAD 2.5M
- SRRK 3.8M
- Earning Date
- ACAD 11-05-2025
- SRRK 11-11-2025
- Dividend Yield
- ACAD N/A
- SRRK N/A
- EPS Growth
- ACAD 615.00
- SRRK N/A
- EPS
- ACAD 1.33
- SRRK N/A
- Revenue
- ACAD $1,018,885,000.00
- SRRK N/A
- Revenue This Year
- ACAD $14.01
- SRRK N/A
- Revenue Next Year
- ACAD $11.81
- SRRK $1,849.81
- P/E Ratio
- ACAD $15.76
- SRRK N/A
- Revenue Growth
- ACAD 14.41
- SRRK N/A
- 52 Week Low
- ACAD $13.40
- SRRK $22.71
- 52 Week High
- ACAD $26.65
- SRRK $46.98
- Technical
- Relative Strength Index (RSI)
- ACAD 43.19
- SRRK 34.63
- Support Level
- ACAD $20.33
- SRRK $29.00
- Resistance Level
- ACAD $22.10
- SRRK $43.48
- Average True Range (ATR)
- ACAD 0.78
- SRRK 2.87
- MACD
- ACAD 0.08
- SRRK -1.26
- Stochastic Oscillator
- ACAD 58.09
- SRRK 2.02
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.